IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Escobar, Miguel [1 ]
Agrawal, Neha [2 ]
Chatterjee, Sagnik [2 ]
Bhattacharya, Swastik [2 ]
Caicedo, Jorge [3 ]
Bullano, Michael [3 ]
Schultz, Robert G. [3 ]
机构：
[1] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA
[2] Complete HEOR Solut, New Wales, PA USA
[3] Takeda Pharmaceut USA Inc, Lexington, MA USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2023年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [31] COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Cortesi, P. A.
    Castaman, G.
    Mantovani, L. G.
    VALUE IN HEALTH, 2020, 23 : S696 - S696
  • [32] CHANGES IN INHIBITORS AFTER RE-EXPOSURE TO FACTOR VIII CONCENTRATE DURING EMICIZUMAB PROPHYLAXIS IN CHILDREN WITH HEMOPHILIA A WITH INHIBITORS
    Kodera, Asami
    Sato, Atsushi
    Hayasaka, Hiroe
    Ogawa, Maki
    Nanjo, Yuka
    Suzuki, Tasuku
    Suzuki, Nobu
    Onuma, Masaei
    Rikiishi, Takeshi
    Imaizumi, Masue
    PEDIATRIC BLOOD & CANCER, 2024, 71 : S101 - S102
  • [33] Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab
    Miller, Connie H.
    Boylan, Brian
    Payne, Amanda B.
    Driggers, Jennifer
    Bean, Christopher J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2021, 43 (02) : E84 - E86
  • [34] Emicizumab Prophylaxis in Hemophilia A with Inhibitors REPLY
    Oldenburg, Johannes
    Levy, Gallia G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2194 - 2195
  • [35] Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors
    Allah, M. Nasr
    Pieragostini, R.
    Oka, G.
    Batista, R.
    Stieltjes, N.
    Lopez, I.
    ANNALES PHARMACEUTIQUES FRANCAISES, 2022, 80 (06): : 915 - 922
  • [36] Reliable Routine Prophylaxis, Relief for Patients Clinical Experience with Emicizumab in Hemophilia A without Inhibitors
    Neubacher, Daniel
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (04) : 294 - 297
  • [37] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    HAEMOPHILIA, 2020, 26 (01) : 41 - 46
  • [38] Additional use of Factor VIII to a Patient with Severe Hemophilia a Receiving Emicizumab Prophylaxis from Infancy
    Yagi, Takeshi
    Matsuda, Takehiro
    Inamine, Itsuki
    Higa, Takeshi
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [39] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
    Pipe, S. W.
    Collins, P.
    Dhalluin, C.
    Kenet, G.
    Schmitt, C.
    Buri, M.
    Jimenez-Yuste, V.
    Peyvandi, F.
    Young, G.
    Oldenburg, J.
    Mancuso, M. E.
    Kavakli, K.
    Kiialainen, A.
    Niggli, M.
    Chang, T.
    Lehle, M.
    Fijnvandraat, K.
    HAEMOPHILIA, 2024, 30 : 24 - 25
  • [40] Prevention of Bleeding in Patients with Moderate and Severe Hemophilia A Playing Sports: A Comparison between Factor VIII and Emicizumab Prophylaxis (STEP: SporTs Emicizumab Prophylaxis)
    Chitlur, Meera B.
    BLOOD, 2022, 140 : 5619 - 5620
12345